Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment With Olverembatinib in Chronic Phase Chronic Myeloid Leukemia Patients Who Failed to at Least Two Previously Administered Second-generation Tyrosine Kinase Inhibitors: a Prospective, Single-arm Clinical Trial.

NCT05311943 is registered in ClinicalTrials.gov with Shenzhen Second People's Hospital as lead sponsor.

NCT NCT05311943
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05311943 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment With Olverembatinib in Chronic Phase Chronic Myeloid Leukemia Patients Who Failed to at Least Two Previously Administered Second-generation Tyrosine Kinase Inhibitors: a Prospective, Single-arm Clinical Trial.
Lead sponsor
Shenzhen Second People's Hospital
Phase
Phase 3
Overall status
Unknown status
Start date
July 1, 2022
Completion date
June 30, 2025
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloid leukemia, chronic phase, olverembatinib, tyrosine kinase inhibitors